Barber said Aquestive updated Anaphylm's packaging, labeling and instructions and then completed a human factors validation study. Aquestive maintained 2026 revenue guidance of $46 million to $50 million. Research and development expense declined slightly to $4 million from $4.1 million, while selling, general and administrative expense increased to $14.1 million from $12.7 million. About Aquestive Therapeutics (NASDAQ:AQST)Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. The article "Aquestive Therapeutics Q2 Earnings Call Highlights" was originally published by MarketBeat.